WU-CART-007

Vironexis Biotherapeutics' VNX-101, an AAV vector-based gene therapy, received FDA clearance for a phase 1/2 trial in CD19+ acute lymphoblastic leukemia. CARsgen completed patient enrollment in a pivotal phase 2 trial for satricabtagene autoleucel in China for advanced gastric/gastroesophageal cancer. Adaptimmune's TCR T-cell therapy afami-cel received FDA approval for synovial sarcoma. Mustang Bio's MB-106 CAR-T therapy achieved a 90% response rate in Waldenstrom macroglobulinemia patients. Wugen's WU-CART-007 showed improved overall response rates with an enhanced lymphodepletion regimen in T-cell malignancy patients.